StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

Equities researchers at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.

Other equities analysts have also recently issued reports about the company. D. Boral Capital reissued a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a report on Thursday, February 6th. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Trading Up 2.3 %

Shares of VNRX opened at $0.58 on Monday. The company has a market cap of $53.29 million, a PE ratio of -1.60 and a beta of 1.20. The stock has a 50-day moving average price of $0.61 and a 200-day moving average price of $0.65. VolitionRx has a 12-month low of $0.43 and a 12-month high of $1.10.

Insiders Place Their Bets

In other news, Director Guy Archibald Innes acquired 174,764 shares of VolitionRx stock in a transaction that occurred on Monday, December 9th. The stock was bought at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the transaction, the director now owns 617,085 shares in the company, valued at $351,738.45. The trade was a 39.51 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Cameron John Reynolds acquired 139,811 shares of VolitionRx stock in a transaction that occurred on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, with a total value of $79,692.27. Following the transaction, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at $1,206,920.28. The trade was a 7.07 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 358,266 shares of company stock valued at $204,212. 12.80% of the stock is currently owned by corporate insiders.

Institutional Trading of VolitionRx

Hedge funds have recently bought and sold shares of the company. Lagoda Investment Management L.P. increased its position in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after buying an additional 1,481,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after acquiring an additional 95,900 shares during the period. Millennium Management LLC bought a new position in VolitionRx during the fourth quarter valued at approximately $36,000. Two Sigma Securities LLC bought a new position in VolitionRx during the fourth quarter valued at approximately $29,000. Finally, Northern Trust Corp boosted its stake in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after buying an additional 28,579 shares during the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.